To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Mise à jour : Il y a 4 ans
Référence : NCT01101165

Femme et Homme

Extrait

The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fasted state.


Critère d'inclusion

  • Healthy

Liens